The purpose of this study is to evaluate the implementation and clinical outcomes of expanded pre-exposure prophylaxis delivery modalities and service delivery points offering long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high-priority groups through diverse delivery channels.
Age range
15 Years – 110 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Pre-exposure prophylaxis uptake by modality
Timeframe: 12 months after enrollment
Pre-exposure prophylaxis uptake by delivery channel
Timeframe: 12 months after enrollment
Pre-exposure prophylaxis uptake by population
Timeframe: 12 months after enrollment
Pre-exposure prophylaxis continuation by modality
Timeframe: 12 months after enrollment
Pre-exposure prophylaxis continuation by delivery channel
Timeframe: 12 months after enrollment
Pre-exposure prophylaxis continuation by population
Timeframe: 12 months after enrollment
Rates of switching between oral and injectable pre-exposure prophylaxis
Timeframe: 18 months after enrollment